Chronic Kidney Disease Stage 5
Conditions
Keywords
Chronic Kidney Disease Stage 5, Hemodialysis, pegloticase
Brief summary
This is a Phase 1 single dose study conducted to evaluate the PK and PD of pegloticase administered to hemodialysis patients. A single dose of pegloticase will be administered intravenously to male or female hemodialysis patients (N = 12) starting 3 hour prior to dialysis. The study consists of a Screening Period, a Treatment Period, and Follow up Period.
Detailed description
End stage renal disease (ESRD) patients that require hemodialysis typically undergo hemodialysis treatment 3 times per week. As such, medications can be dialyzed off, reducing their clinical effectiveness; this study is being conducted to understand how dialysis affects the pharmacokinetics (PK) and pharmacodynamics (PD) of pegloticase.
Interventions
DRUGPegloticase
a single 8 mg iv (in the vein) dose before hemodialysis session
Sponsors
Savient Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. 18 and 75 years of age, inclusive 2. Agrees to employ best possible methods to abstain from becoming pregnant or impregnating another. 3. Stage V chronic kidney patients with minimal or no residual renal function receiving hemodialysis and stable on hemodialysis (3x week) 4. BMI = 18.5 kg/m2 to \< 45 kg/m2
Exclusion criteria
1. Any surgical or medical condition that may interfere with drug absorption, distribution, metabolism, or excretion, or any other condition that may place the subject at risk 1. Glucose-6-phosphate dehydrogenase (G6PD) deficiency 2. Uncontrolled congestive heart failure 3. Refractory chronic gout 2. History of drug and/or alcohol abuse within 6 months prior to screening 3. History of or current clinically significant mental disorder or an antagonistic personality that compromises the validity of the informed consent 4. Donation of blood or plasma within 30 days prior to dosing 5. History of or current hepatitis, or carriers of hepatitis B surface antigen (HbsAg) and/or hepatitis C antibodies (anti-HC). 6. Use of an investigational drug or product, within 30 days 7. History of clinically significant drug allergies or sensitivities 8. Females with a positive pregnancy test or who are breast feeding at Screening or plan to breast feed within 30 days of dosing 9. A baseline QTc interval ≥ 490 milliseconds for males and ≥ 510 milliseconds for females 10. Is unable to refrain from alcohol 11. Has taken any prescription or over the counter medication within 7 days prior to treatment day that, in the opinion of the Investigator, could be expected to confound the PK or metabolism of the study drug 12. Has taken the following herbal agents or nutraceuticals within 7 days prior to Screening: chapparal, comfrey, germander, gin bu huan, kava, pennyroyal, skullcap, St. John's Wort, or valerian 13. Has poorly controlled malignant hypertension (systolic blood pressure \[SBP\] \> 200 mm Hg and/or diastolic blood pressure \[DBP\] \> 120 mm Hg, 14. Concurrent use of urate-lowering drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • To evaluate the pharmacokinetics (PK) of pegloticase after a single-dose administration to hemodialysis patients when administered starting 3 hours before dialysis | 1 month |
Secondary
| Measure | Time frame |
|---|---|
| • To evaluate the pharmacodynamics (PD) of pegloticase and SUA, before and after hemodialysis sessions | 1 month |
Countries
United States
Outcome results
None listed